Join NETRF’s ‘Research Changes Lives’ Giving Tuesday Campaign—Every gift doubled now through December 3, 2024. LEARN MORE

Home
About NETRF

About
NETRF

Our Story

NETRF Team

Board of Directors

Board of Scientific Advisors

Diversity & Inclusion

Financial Stewardship & Accountability

Careers at NETRF

The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.

DONATE
For Patients
Our Research

For Researchers

About our Research

Our Strategy

Our Impact

Research Portfolio

Funding for Researchers

Apply for Grants

Research Symposium

The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.

DONATE
Get Involved

Get
Involved

Support NET Research

Give Now

Ways to Give

What Your Gift Supports

Donor Stories

Fundraising Events

Memorial Gifts

Everlasting Impact Tributes

Planned Giving
Events

2022 Symposium Posters

Home » For Researchers » Past Symposia » 2022 Research Symposium » 2022 Virtual Research Symposium Videos » 2022 Symposium Posters

2022 Hybrid Research Symposium Posters

The 2022 NETRF Hybrid Research Symposium poster session was held at the Boston meeting for presenters that attended in-person, however, all posters were viewable online through the virtual Symposium platform.

Please note that some presenters chose not to post their presentations online following the meeting and have been respectfully omitted here.

Search by Session or by Name:

Evaluation of DOTATATE-PET After Two Cycles of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NETs)

Presenter: Duan

Evaluation of Cases with Neuroendocrine Cell Hyperplasia for Classification as Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and Subsequent Whole Exome Sequencing Analysis

Presenter: Merrick

Effect of Epigenetic Treatment on SST2 Expression in Neuroendocrine Tumor Patients

Presenter: Refardt

Economic disparity lowers neuroendocrine cancer diagnosis

Presenter: Skill

An in vitro/in vivo platform to test the anti-tumor activity of tyrosine kinase inhibitors in medullary thyroid cancer

Presenter: Vitale

A novel anti-SSTR bispecific T-cell engager (BiTEÂ®)-like molecule for the treatment of neuroendocrine tumors

Presenter: Pelle

A Human Pluripotent Stem Cell-based Model for Lung Carcinoid

Presenter: Chen

3p C NETA TATE: A versatile somatostatin analogue for Al 18 F labeled and therapeutic SSTR2 targeting radiopharmaceuticals

Presenter: Cleeren

Confidentiality Policy

Confidentiality Policy

The Neuroendocrine Tumor Research Foundation is the world’s leading non-governmental supporter of research into the causes, treatments, cure, and prevention of neuroendocrine cancer. To further enable its important mission, NETRF convenes a premier Annual Scientific Conference for its funded investigators and select invited guests that aims to stimulate the open exchange of scientific information, to promote collaborations and to spark discussions of novel approaches to understanding and treating NETs. In an attempt to allow for an open discussion and sharing of unpublished data, NETRF requests that, as a participant in the annual NETRF Symposium (the “Symposium”), you commit to hold in confidence all Confidential Information (as defined below) sent in advance of, and presented at, the Symposium. To ensure such confidentiality, NETRF has created the following confidentiality policy and asks that you, as a party who will see and receive Confidential Information as an attendee and/or participant at the Symposium (a “Receiving Party”), sign this confidentiality agreement (“Agreement”), acknowledging that you have read, understand and
agree to the terms below. Furthermore, because photos and videos will be taken at the Symposium NETRF also requires attendee acceptance of its Media Release Policy, which is provided below, and requires your acknowledgement indicating that you have read, understand and agree to its terms.

As a participant of the NETRF Symposium, Receiving Party understands that he/she will be exposed to, and possibly receive, Confidential Information and/or unpublished data, the disclosure or use
of which may be prejudicial or harmful to the disclosing party (“Disclosing Party”) and to the goals and work of NETRF. This Agreement is effective as of the date on which it has been signed below (the “Effective Date”) and shall govern the conditions of receipt or disclosure of all information received by or disclosed to attendees (including the undersigned) in connection with the NETRF Symposium.
“Confidential Information” means the information provided at the NETRF Symposium (including through such means as meetings, websites, emails, or handouts) that:
- relates to proprietary and confidential clinical trial data, and
- is designated as confidential by the Disclosing Party or NETRF prior to or contemporaneously with disclosure of such information to the Receiving Party; or
- is designated as confidential by the Disclosing Party or NETRF within a reasonable period of time after the disclosure of such information; provided, however, that such information shall in such cases only become Confidential Information as of the time the designation as confidential is communicated to the attendee/participant; or
- would be apparent to a reasonable person having the professional and scientific background, training, experience and knowledge of the Receiving Party that such information is of a confidential or proprietary nature and the maintenance of which would be important to the Disclosing Party.
Receiving Party hereby agrees that, for a period of five (5) years from the Effective Date, he/she:
- shall hold Confidential Information in confidence,
- shall not use or exploit Confidential Information for his/her own benefit or for the benefit of another without the prior written consent of the Disclosing Party, and
- shall not disclose Confidential Information to any other person without the express written consent of the. Confidential Information shall not include information that Receiving Party can demonstrate by written records: Notwithstanding the above, Receiving Party:
- may retain a single copy of the Disclosing Party’s Confidential Information for the sole purpose of ascertaining its ongoing rights and responsibilities in respect of such information; and
- shall not be required to destroy any computer files stored securely by the Receiving Party or its Affiliates that are: (x) created during automatic system back up; or (y) retained for legal purposes by the legal division of the Receiving Party and its Affiliates.